Cabozantinib
Brand names: Omcazio · Active ingredient: Cabozantinib Laurylsulfate
In short: OMCAZIO is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). OMCAZIO, in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced RCC.
What is Cabozantinib used for?
OMCAZIO is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC).
OMCAZIO, in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced RCC.
OMCAZIO is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
OMCAZIO is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
âš Boxed warning (FDA's strongest warning)
OMCAZIO is not substitutable on a mg-to-mg basis with other cabozantinib products. Inappropriate substitution or incorrect conversion of OMCAZIO capsules for another cabozantinib product can increase the risk of serious adverse reactions. Confirm that the intended cabozantinib product at the intended dosage and strength is being prescribed and dispensed. (
2.1,
2.3,
5.1)
Cabozantinib dosage
Cabozantinib is available in multiple dosage forms and strengths. Recommended dosages depend on the specific cabozantinib product prescribed.
OMCAZIO is
NOTsubstitutable on a mg-to-mg basis with other cabozantinib products
.
To avoid medication errors, including overdosage or underdosage, prescribe the recommended dosage specific for OMCAZIO
.
OMCAZIO may be taken with or without food
.
Swallow OMCAZIO capsules whole. Do not crush, chew, or open OMCAZIO capsules.
If a dose of OMCAZIO is missed, take the missed dose as soon as possible. If a dose is missed by more than 12 hours, skip the missed dose and take the next dose at the scheduled time. Do not take 2 doses at the same time to make up for the missed dose.
Stop OMCAZIO at least 3 weeks prior to scheduled surgery, including dental surgery to reduce the risk of hemorrhage. Do not administer OMCAZIO for at least 2 weeks after major surgery and until adequate wound healing
.
The recommended dosages of OMCAZIO are presented in Table 1.
Indication | Recommended Dosage | Duration
Renal Cell Carcinoma | Single Agent
34.5 mg orally once daily | Until disease progression or unacceptable toxicity
Combination Therapy
23 mg orally once daily in combination with nivolumab or nivolumab and hyaluronidase-nvhy
Refer to the Prescribing Information for nivolumab or nivolumab and hyaluronidase-nvhy for the recommended dosage information. | Until disease progression or unacceptable toxicity
Hepatocellular Carcinoma | 34.5 mg orally once daily | Until disease progression or unacceptable toxicity
Extra-pancreatic Neuroendocrine Tumors | Adult Patients and Pediatric Patients 12 years of age and older with bodyweight greater than or equal to 40 kg
34.5 mg orally once daily
Pediatric patients 12 years of age and older with bodyweight less than 40 kg
23 mg orally once daily | Until disease progression or unacceptable toxicity
If converting from CABOMETYX, discontinue CABOMETYX, and use Table 2 to determine OMCAZIO dosage based on dosage equivalence.
CABOMETYX tablets dosage | OMCAZIO capsules dosage
60 mg once daily | 34.5 mg once daily
40 mg once daily | 23 mg once daily
20 mg once daily | 11.5 mg once daily
Withhold OMCAZIO for:
Intolerable Grade 2 adverse reactions
Grade 3 or 4 adverse reactions
Osteonecrosis of the jaw
Thrombotic microangiopathy
Upon resolution/improvement (i.e., return to baseline or resolution to Grade 1) of an adverse reaction, reduce the dose as follows:
The recommended dosage reduction levels for OMCAZIO for adverse reactions are listed in Table 3. …
How to take Cabozantinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Risk of Medication Errors and Important Administration Information: Advise patients that OMCAZIO is not substitutable with other cabozantinib products on a mg-to-mg basis. Advise patients to take OMCAZIO exactly as prescribed
. Advise patients to swallow the capsules whole with water and not to crush, chew, or open the capsules. Advise patients to take OMCAZIO with or without food
.
Hemorrhage: Instruct patients to contact their healthcare provider to seek immediate medical attention for signs or symptoms of unusual severe bleeding or hemorrhage
.
Perforations and fistulas: Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during OMCAZIO treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain
.
Thromboembolic events: Inform patients of the risk of arterial and venous thromboembolic events. Advise patients to immediately contact their health care provider for signs and symptoms suggestive of a blood clot such as dyspnea, chest pain, or localized limb edema
. …
Warnings & precautions
Do not take this medicine if: None.
Cabozantinib is available in multiple dosage forms and strengths. The recommended dosage depends on the specific cabozantinib product prescribed. OMCAZIO is not substitutable on a mg-to-mg basis with other cabozantinib products
. Inappropriate substitution or incorrect conversion of OMCAZIO capsules for another cabozantinib product can:
Increase the risk of serious adverse reactions OR
Reduce its effectiveness.
Confirm that the intended cabozantinib product at the intended dosage and strength is being prescribed and dispensed.
OMCAZIO can cause severe and fatal hemorrhages.
Do not administer OMCAZIO to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.
The incidence of Grade 3 to 5 hemorrhagic events was 5% in cabozantinib-treated patients in RCC and HCC studies
.
Withhold OMCAZIO for 3 weeks prior to scheduled surgery, including dental surgery to reduce the risk of hemorrhage. Permanently discontinue OMCAZIO for Grade 3 or 4 hemorrhage and prior to surgery as recommended
.
OMCAZIO can cause gastrointestinal (GI) perforations and fistulas.
Fistulas, including fatal cases, occurred in 1% of cabozantinib-treated patients
. GI perforations, including fatal cases, occurred in 1% of cabozantinib-treated patients.
Monitor patients for signs and symptoms of fistulas and perforations, including abscess and sepsis. Permanently discontinue OMCAZIO in patients who experience a Grade 4 fistula or a GI perforation
.
OMCAZIO can cause arterial or venous thromboembolic events.
Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism occurred in 2% of cabozantinib-treated patients. Fatal thromboembolic events occurred in cabozantinib-treated patients
. …
Cabozantinib side effects
The following clinically significant adverse reactions are discussed elsewhere in the labeling:
Hemorrhage
Perforations and Fistulas
Thromboembolic Events
Hypertension and Hypertensive Crisis
Cardiac Failure
Diarrhea
Palmar-Plantar Erythrodysesthesia
Hepatotoxicity
Adrenal Insufficiency
Proteinuria
Thrombotic Microangiopathy
Osteonecrosis of the Jaw
Impaired Wound Healing
Reversible Posterior Leukoencephalopathy Syndrome
Thyroid Dysfunction
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of OMCAZIO (cabozantinib) capsules has been established from adequate and well-controlled studies of CABOMETYX
®(cabozantinib) tablets, which has different recommended dosages than OMCAZIO.
The data described in the WARNINGS AND PRECAUTIONS section and below reflect the adverse reactions of CABOMETYX
®(cabozantinib) tablets in these adequate and well-controlled studies. …
Drug interactions
Strong CYP3A Inhibitors
Avoid coadministration of OMCAZIO with strong CYP3A inhibitors. If coadministration cannot be avoided, reduce the dosage of OMCAZIO
.
Cabozantinib is a CYP3A substrate. Coadministration with a strong CYP3A inhibitor increases cabozantinib exposure
, which may increase the risk of OMCAZIO-associated adverse reactions.
Strong or Moderate CYP3A Inducers
Avoid coadministration of OMCAZIO with strong or moderate CYP3A inducers. If coadministration cannot be avoided, increase the dosage of OMCAZIO
.
Cabozantinib is a CYP3A substrate. Coadministration with a strong CYP3A inducer decreases cabozantinib exposure, which may reduce effectiveness of OMCAZIO
.
About this medicine
OMCAZIO is the laurylsulfate salt of cabozantinib, a kinase inhibitor. Cabozantinib laurylsulfate is described chemically as
N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Laurylsulfate. The molecular formula is C
40H
50FN
3O
9S and the molecular weight is 767.9 Daltons as laurylsulfate salt. The chemical structure of cabozantinib laurylsulfate salt is:
Cabozantinib laurylsulfate salt is a white to off-white solid that is practically insoluble in aqueous media.
OMCAZIO (cabozantinib) capsules for oral use are supplied as hard gelatin capsules containing 11.5 mg, 23 mg, or 34.5 mg of cabozantinib, which is equivalent to 17.6 mg, 35.2 mg, or 52.8 mg of cabozantinib laurylsulfate, respectively.
OMCAZIO also contains the following inactive ingredient: ammonia solution, ascorbic palmitate, black iron oxide, FD&C Blue #1, gelatin, polyoxyl 32 stearate, potassium hydroxide, propylene glycol, shellac, titanium dioxide, and tocopherol. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c0a58965-24c8-4f4e-ac71-9b36226c7b18. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate